Nanocomposite vaccine adjuvant assists in antiviral therapy
Problem and implemented solution
Subunit vaccine antigens are usually combined with adjuvants to enhance the efficacy of vaccines. Aluminum adjuvants (Alum) are currently the most widely used adjuvants. In long-term use, it has been found that Alum can stimulate the body to produce potent Th2-mediated humoral immunity; however Alum is difficult to stimulate sufficient Th1 type cell immune responses, which affects the effectiveness of antiviral therapy. This solution award has developed a novel layered Mg/Al double hydroxide (LDH)-nucleic acid nanocomposite vaccine adjuvant. This nanoadjuvant is supported by LDH and adsorbs a large amount of antigens and DNA long chains containing CpG ODN immune adjuvant through electrostatic interactions. In terms of immune activation, Mg/Al LDH plays a role similar to Alum, assisting antigens in inducing strong humoral immune responses; Meanwhile, CpG ODN induces efficient cellular immune response by binding to TLR-9 on lysosomal membrane, achieving activation of Th1 type immune response. Compared to traditional Alum, this nanoadjuvant has better immune therapeutic effects and assists in antiviral therapy.
Nomination
Biotechnology And National Health
Topic
Technologies for human health
Estimated duration of implementation
2025-2035
Implementation geography
Beijing, China
Description of competitive advantages
The composite nanoadjuvant has been proven to have a co-activation effect of humoral immunity and cellular immunity at the in vivo level, and the cellular immunity level is significantly better than that of traditional Alum, with a long-term immune activation effect. This indicates that this solution award can effectively compensate for the shortcomings of traditional Alum in Th1 immune response, and the preparation process is simple, the process is controllable, and has broad application prospects.
List of awards and prizes, media articles about the organization/individual or the Practice
N.A.
List of scientific works and IP connected with the Practice
N.A.
